The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback